• Respi DART 2022: Speaker Evaluation and Needs Assessment

    Thank you for attending the Respi DART 2022. Please take a few minutes to complete our after-session survey as it will help us improve future Respi DART meetings and offer relevant content to our attendees.
  • About you: Please select your professional role (single choice)*

  • Have you been to a DART conference before?*
  • What is your area of expertise*

  • Are you an industry professional?*

  • Session 1: Advances in SARS-CoV-2 antiviral modalities

    Tuesday, Dec 6, 2022, 15:00-16:25
  • Plenary lecture: SARS-CoV-2 therapeutics, replicons, and drug resistance:Stefan Sarafianos, Emory University, USA
    Rows
  • Pan-coronavirus protease inhibitors: Ladislau Kovari, Wayne State University, USA
    Rows
  • Mechanism of B cell fatty acid metabolism that enables production of antibodies in response to COVID-19 vaccination: Andrea Cox, Johns Hopkins University, USA
    Rows

  • Session 2: Respiratory viruses in children and inflammation

    Monday, Dec 5, 2022, 16:50-17:50
  • Plenary lecture: Successful research takes a village: Longitudinal surveillance of SARS-CoV-2 antibodies in pediatric healthcare workers study: Claudia Morris, Emory University, USA
    Rows
  • Inflammatory response in response to SARS-CoV-2 and influenza: Rabindra Tirouvanziam, Emory University, USA
    Rows

  • Barry-Wainberg DART Achievement Award Session

    Wednesday, Dec 7, 2022, 8:00-8:50
  • Gertrude Elion Distinguished Lecturer Award Lecture Recipient: Christian Bréchot, University of South Florida, USA
    Rows

  • Session 3: Animal disease models and Long COVID-19

    Wednesday, Dec 7, 2022, 8:50-10:10
  • Plenary Lecture: Coronavirus variants and Long COVID in animal models: Ralph Baric, University of North Carolina at Chapel Hill, US
    Rows
  • Coronavirus animal models and pathogenesis: Stanley Perlman, University of Iowa, USA
    Rows
  • Long COVID affecting major organs early impacts: Michael Peluso, University of California San Francisco, US
    Rows

  • Session 4: Industry Session: Therapeutics against respiratory viruses: Clinical advances an industry perspective (non-CME session)

    Wednesday, Dec 7, 2022, 10:40-12:15
  • The story of Nirmatrelvir and Paxlovid: Dafydd Owen, Pfizer, USA
    Rows
  • Advances in COVID-19 diagnosis: Gavin Cloherty, Abbott, USA
    Rows
  • Aligos program: Jerome Deval, Aligos Therapeutics, USA
    Rows
  • Vir Biotechnology: Wendy Yeh, Vir Biotechnology, USA
    Rows
  • TBD (MERCK): Daria Hazuda
    Rows
  • New advances in RSV vaccine development: Martin Moore, Meissa Vaccines, USA
    Rows

  • Respi DART 2022 Poster Session

    Wednesday, Dec 7, 2022, 15:15-16:45
  • Poster Session
    Rows

  • Session 5: Host-virus interactions and basic science discoveries

    Wednesday, Dec 7, 2022, 16:45-17:35
  • Plenary Lecture: Host virus interactions: comparing and contrasting SARS-2,MERS and OC43: Susan Weiss, University of Pennsylvania, USA
    Rows
  • Interferons and SARS-CoV-2 in terms of pathogenesis and therapeutics: Jordan Feld, Toronto General Hospital Research Institute, Canada
    Rows

  • Oral Abstract: Session 1

    Wednesday, Dec 7, 2022, 17:35-18:05
  • Oral abstract 1
    Rows
  • Oral abstract 2
    Rows
  • Oral abstract 3
    Rows

  • Session 6: Immunology and advances in vaccine development

    Thursday, Dec 8, 2022, 9:00-10:30
  • Plenary lecture: The systemic pathogenesis of pandemic influenza: Debby Van Riel, Erasmus MC, Netherlands
    Rows
  • Sex differences in immune responses against influenza infection and vaccination: Sabra Klein, John Hopkins Bloomberg School of Public Health, USA
    Rows
  • Special Lecture: On Monkey Pox Virus- Vaccines and Therapeutics for Monkeypox Viruses Infections: Rachel Roper, East Carolina University, USA
    Rows

  • Oral Abstract Session 2

    Thursday, Dec 8, 2022, 11:30-12:30
  • Oral abstract 4
    Rows
  • Oral abstract 5
    Rows
  • Oral abstract 6
    Rows
  • Oral abstract 7
    Rows
  • Oral abstract 8
    Rows
  • Oral abstract 9
    Rows

  • Needs Assessment

  • Please rate to which extent you agree with the following statement:
    Rows
  • The following meeting objectives were met during Respi DART 2022:
    Rows
  • What needs/ gaps do you feel currently exist in this field of research?
    Rows
  • Do you feel that the Respi DART 2022 program successfully addressed the following needs/ gaps in knowledge?
    Rows

  • Intent to Change

  • Please rate to which extent you agree with the following statements:
    Rows

  • Overall Meeting Experience

  • Please rate to which extent you agree with the following statements:
    Rows

  • Logistics Experience

  • Please rate to which extent you agree with the following statements:
    Rows

  • Your feedback is extremely important to us and will help improve the program for future years. Thank you for Completing the Survey for Respi DART 2022!

     

    Happy Holidays!

    Conference Secretariat

    Respi DART 2022

  • Should be Empty: